The American Association for the Study of Liver Diseases, Infectious Disease Society-USA and International Antiviral Society-USA are collaborating to update hepatitis C treatment guidelines in light of new, effective treatments, according to a Medscape report.
The new generation of HCV drugs is undoubtedly effective, but expensive. The three medical societies plan to update their treatment guidelines by adding a section on cost-effective treatment.
The updated guideline, still in draft form, is being designed to inform physicians of the economics of HCV treatment, rather than dictate how treatment decisions should be made, according to the report.